title: Benefit of nanocarrier of magnetic magnesium in rat malathion-induced toxicity and cardiac failure using non-invasive monitoring of electrocardiogram and blood pressure.
abstract: Medical management in acute organophosphate (OP) poisoning is not always successful because of tissue hypoxia which results in a reduction of heart contractility and cell damage. This study reports improvement of malathion (MAL)-induced cardiac failure by a nanocarrier of magnetic isotope of Mg (PMC16). A rat model of acute MAL poisoning was set up. PMC16 nanoparticle at doses of 0.05, 0.1, 0.2 LD50 = 896 mg/kg) were administered intravenously (iv) 30 minutes after a single intraperitoneal (ip) injection of MAL (0.25 LD50= 207 mg/kg). Atropine (AT; 40 mg/kg, ip) plus pralidoxime (PAM; 40 mg/kg, ip) and magnesium sulfate (MgSO₄; 600 mg/kg, iv) were used as standard therapy or controls. Anesthetized animals were monitored for heart rate, electrocardiogram, blood pressure, and blood oxidative stress biomarkers like cellular lipid peroxidation, total thiol molecules, antioxidant power, gamma glutamil transpeptidase, and acetylcholinesterase (AChE) as a marker of OP toxicity. Results indicated that after MAL administration, heart rate and BP decreased and R-R duration increased. PMC16 markedly restored BP at all doses as compared with MgSO₄. PMC16 at the dose of 0.05 LD50 significantly increased BP in comparison to AT + PAM. PMC16 restored heart rate at dose of 0.2 LD50 and reduced lipid peroxidation at dose of 0.05 LD50 as compared to MgSO₄. PMC16 also improved total antioxidant power at all doses when compared to AT + PAM and reduced GGT activity at dose of 0.2 LD50 but did not affect total thiol molecules. MgSO₄ could improve MAL-induced reduction of total antioxidant power. After 24 h, PMC16 significantly improved MAL-suppressed AChE activity at doses of 0.05 and 0.1 LD50. PMC16 at all doses significantly recovered MAL-induced arrhythmia when compared to standard therapies. It is concluded that PMC16 is able to control OP-induced cardiac failure and toxicity.
authors.affiliation: Faculty of Pharmacy, Pharmaceutical Sciences Research Center, Tehran University of Medical Sciences, Tehran, Iran.
authors.forename: Hamidreza
authors.initials: H
authors.lastname: Mohammadi
authors.forename: Gholamreza
authors.initials: G
authors.lastname: Karimi
authors.lastname: Seyed Mahdi Rezayat
authors.lastname: Ahmad Reza Dehpour
authors.forename: Hoda
authors.initials: H
authors.lastname: Shafiee
authors.forename: Shekoufeh
authors.initials: S
authors.lastname: Nikfar
authors.forename: Maryam
authors.initials: M
authors.lastname: Baeeri
authors.forename: Omid
authors.initials: O
authors.lastname: Sabzevari
authors.forename: Mohammad
authors.initials: M
authors.lastname: Abdollahi
mesh_terms: D000110:Acetylcholinesterase / Q000097:blood; D000818:Animals; D000975:Antioxidants / Q000032:analysis / Q000494:pharmacology; D001285:Atropine / Q000494:pharmacology; D015415:Biomarkers / Q000097:blood; D001794:Blood Pressure / Q000187:drug effects; D004195:Disease Models, Animal; D004562:Electrocardiography / Q000187:drug effects; D006333:Heart Failure / Q000139:chemically induced* / Q000188:drug therapy*; D006339:Heart Rate / Q000187:drug effects; D007928:Lethal Dose 50; D015227:Lipid Peroxidation; D008274:Magnesium / Q000494:pharmacology*; D008278:Magnesium Sulfate / Q000494:pharmacology; D008280:Magnetics; D008294:Malathion / Q000633:toxicity*; D008297:Male; D053768:Metal Nanoparticles / Q000737:chemistry*; D018384:Oxidative Stress / Q000187:drug effects; D011220:Pralidoxime Compounds / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013438:Sulfhydryl Compounds / Q000097:blood
chemical_list: D000975:Antioxidants; D015415:Biomarkers; D011220:Pralidoxime Compounds; D013438:Sulfhydryl Compounds; D008278:Magnesium Sulfate; D001285:Atropine; D000110:Acetylcholinesterase; D008274:Magnesium; C028797:pralidoxime; D008294:Malathion